Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

VCPro Database 2014 (17th Edition) Now Available! Newly released


Venture Capital Deals Spreadsheet Now Available Newly released


 

MicroBiome Therapeutics™ Completes Bridge Financing

--Supports Completion of Ongoing Clinical Studies and Preparations for Further Trials of Microbiome Modulator NM504 for Prediabetes and Type 2 Diabetes--

--Company to Present at Biotech ShowcaseTM 2014--

BROOMFIELD, Colo., December 16, 2013-- MicroBiome TherapeuticsTM LLC, (MBT) today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

"We welcome our investors' continuing support as we wrap up our pilot studies of NM504 and prepare for the next phase of clinical trials," noted Steve Orndorff, CEO of Microbiome Therapeutics. "Growing evidence supports a role for the gut microbiome in a range of disorders, and interest in the therapeutic potential of microbiome modulators is soaring. These additional funds will enable us to complete our ongoing studies and prepare for our next set of clinical trials. We expect to report results from the current studies soon, prior to the launch of a significant Series B financing during 2014."

NM504 is being studied in two placebo-controlled, double-blinded, proof of concept trials. The first is assessing its ability to alter the gastrointestinal (GI) microbiome to enhance insulin sensitivity and fasting blood glucose levels in prediabetic individuals. The second is testing the utility of NM504 in combination with metformin in diabetes patients with adverse GI effects. NM504 has previously demonstrated the potential to mitigate these adverse effects.

MBT is developing microbiome modulators that alter bacterial populations and their environment in the GI tract to address serious health conditions. The company's microbiome modulators are designed to act on multiple factors in the GI environment, augmenting the growth of targeted desirable bacterial strains and discouraging the growth of others. NM504 is formulated to promote microbiome shifts that positively affect metabolism and weight.

Separately, the company announced that it will be presenting at Biotech ShowcaseTM 2014 in San Francisco on January 13, 2014 at 9:15am PT. For more information, visit ebdgroup.com/bts/index.php

About MicroBiome TherapeuticsTM

MicroBiome Therapeutics LLC (MBT), is a clinical stage biotechnology company developing pharmaceutical and medical food products that aim to improve health status by interacting with and altering the human microbiome. MBT is developing evidence-based microbiome modulators to address serious health conditions. Lead product NM504 is being tested in clinical trials for the management of insulin sensitivity and blood glucose levels and as an adjunct to metformin in patients with prediabetes and type 2 diabetes. For more information, visit www.mbiome.com.

Contact:
Barbara Lindheim
BLL Partners, LLC
blindheim@bllbiopartners.com
212.584.2276 (office)
917.355-9234 (mobile)


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals New
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

Venture Capital StarterPak
VC Pitch
Private Placement Memorandum
Confidentiality Agreement Package
Series A Preferred Term Sheet
Bridge Financing Contract
Employment Agreements
Understanding Employee Stock Options

Business Plan Tools

Free Business Plan Template
Sample Business Plans
Business Plan Pro

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer